Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Iran-Israel War Triggers LPG Shortage Concerns in Major Indian Cities; Centre Steps In
The ongoing conflict in the Middle East involving Iran and Israel has begun to impact India’s hospitality sector, with hotel and restaurant associations in Bengaluru, Chennai, and Mumbai reporting a shortage of...





Discussion about this post